Sage Therapeutics Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Sage Therapeutics press release (SAGE): Q4 GAAP EPS of -$2.12 beats by $0.05.Revenue of $1.6M (-99.9% Y/Y) misses by $0.17M.Ended 2021 with cash balance of $1.7 billion;…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a data rich year marked by important advancements in multiple disease areas across all of our brain health franchises,” said Barry Greene, chief executive officer at Sage Therapeutics. “I’m excite

Smart Beta ETF report for EES

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$2.16 and the consensus…

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability

Sage Therapeutics Inc (SAGE) shares closed 0.3% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently up 2.3% year-to-date, down 49.7% over the past 12 months, and down 24.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Trading Activity Trading volume this week was 46.0% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -123.8% The company's stock price performance over the past 12 months lags the peer average by 63.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -55.6% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Sage Therapeutics Inc (SAGE) shares closed today 17.4% lower than it did at the end of yesterday. The stock is currently up 2.3% year-to-date, down 49.7% over the past 12 months, and down 24.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 rose 0.1%. Trading Activity Shares traded as high as $45.61 and as low as $35.30 this week.Shares closed 59.4% below its 52-week high and 0.3% below its 52-week low.Trading volume this week was 25.4% lower than the 10-day average and 29.7% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -123.8% The company's stock price performance over the past 12 months lags the peer average by 63.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -55.6% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

(Bloomberg) -- Former high flying biotechnology favorites Mirati Therapeutics Inc. and Sage Therapeutics Inc. have lost more than half their value from record highs, hurt by growing pessimism on new medicines as well as the higher rate environment damaging most stocks.